Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical firm primarily dedicated to developing therapies for acute cardiovascular ailments, and secondarily for acute pulmonary diseases. Its prominent therapeutic programs include istaroxime, undergoing Phase IIb clinical trials for acute decompensated heart failure and Phase IIa for early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant in Phase IIb for respiratory distress syndrome in preterm infants; Lyophilized KL4 surfactant, in Phase IIa trials for lung injury stemming from COVID-19; and Rostafuroxin, in Phase IIb for genetically associated hypertension. The company maintains collaborations, including one with Universita degli Studi di Milano-Bicocca for the discovery and advancement of novel SERCA2a compounds targeting chronic and acute human heart failure. It also holds a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and commercialization of a portfolio of potential KL4 surfactant products, and a collaboration with Battelle Memorial Institute to further develop its ADS for its Phase III program. Established in 1992 as Discovery Laboratories, Inc., the company rebranded as Windtree Therapeutics, Inc. in April 2016. It is headquartered in Warrington, Pennsylvania, and operates as a subsidiary of Lee's Pharmaceutical Holdings Limited.
Subscribe to see WINDTREE THERAPEUTICS INC /DE/’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
WINDTREE THERAPEUTICS INC /DE/ is a pharmaceuticals company headquartered in Warrington, United States. It is publicly listed (WINT) with a market capitalisation of $404,505. Xcout tracks 14 named people at WINDTREE THERAPEUTICS INC /DE/, including Jed A. Latkin (Chief Executive Officer, President & Director).
8 more named people on record for WINDTREE THERAPEUTICS INC /DE/, with roles, board committees and tenure — see the full roster →
A few of WINDTREE THERAPEUTICS INC /DE/'s closest competitors — see the full list of competitors and alternatives →
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with idiopathic pulmonary fibrosis. Trevi Therapeutics also possesses a licensing agreement with Endo Pharmaceuticals Inc., granting it the rights to develop and market products containing nalbuphine hydrochloride in various formulations. Established in 2011, the company maintains its corporate headquarters in New Haven, Connecticut.
Sinotherapeutics Inc. is a high-tech pharmaceutical enterprise focused on the research, commercial production, and sales of advanced drug formulations, including anti-infective, anti-tumor, metabolic, and cardiovascular medications. The company also provides innovative drug formulation CRO and CMO services to global patients and pharmaceutical partners.
Established in 2008 and based in Beijing, China, Beijing Kawin Technology Share-Holding Co., Ltd. specializes in the research, development, and manufacturing of pharmaceutical products, with a primary emphasis on treatments for liver conditions within the Chinese market. Its key offerings include recombinant human interferon alfa-2b injection and compound glycyrrhizin. Beyond its own product line, the company supplies active pharmaceutical ingredients (APIs) and delivers comprehensive clinical research services for advancing biological products. These services encompass the fermentation and purification of drug substances, drug product formulation, and the creation of analytical methods. Beijing Kawin also offers contract manufacturing solutions. The company's global footprint includes serving customers in countries such as Pakistan, Colombia, the Philippines, Vietnam, Russia, and Cambodia, among others. Furthermore, it maintains strategic partnerships with entities like Legend Capital, Haitong Capital, and Cybernaut.
SFJ Pharmaceuticals is a privately held pharmaceutical development and investment company that helps advance drug candidates through clinical development and regulatory approval. It serves biotechnology and pharmaceutical partners by providing development funding, operational expertise, and global clinical-trial support.
Avenue Therapeutics, Inc. functions as a specialized pharmaceutical enterprise, primarily dedicated to innovating and bringing to market medical therapies tailored for critical and intensive care environments within hospitals. Their leading product candidate is intravenous Tramadol, a synthetic opioid with a dual mechanism of action, currently undergoing Phase III clinical trials for the management of severe pain experienced by patients after surgery. Established in 2015, the company's operations are based in New York, New York.
Evotec SE operates globally as a dedicated partner, specializing in the discovery and advancement of new pharmaceutical products for the biotechnology and pharmaceutical sectors. Its comprehensive research and development initiatives encompass a broad spectrum of medical areas, such as metabolic disorders (including diabetes and its complications), fibrosis, infectious conditions, central nervous system (CNS) diseases, oncology, pain management, inflammatory ailments, immunological dysfunctions, rare diseases, respiratory conditions, and women's health. The company maintains strategic alliances and collaborations with numerous prominent organizations, including Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd, Kazia Therapeutics, Apeiron Biologics, and Takeda Pharmaceuticals. Established in 1993, the company was formerly known as Evotec AG, changing its name to Evotec SE in April 2019. Its corporate headquarters are located in Hamburg, Germany.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Post the link and the card appears automatically — each network fetches the image itself.